Special Features
Cold Chain MENA 2010
It is estimated that the global biopharma cold chain market will grow to $6.6 billion by 2011. This significant growth can be attributed to the industry’s push into emerging markets like the MENA. The vaccine market, with the outbreak of H1N1 flu has also seen dramatic growth with an estimated 5% growth per year for the next 5 years.Adding to the volume is the regions growth in conducting clinical trials, as many biopharmaceuticals are coming off patent they look to the tax free haven of the MENA region to test and manufacture biosimilars.
The MENA region has identified and reacted to this activity with the development of world class logistics hubs and infrastructure that can facilitate air, ground and ocean carrier modes to the rest of the globe. Including Saudi Arabia’s $26.6 billion King Abdullah Economic City and the more established Jebel Ali Free Zone in the UAE.
As the Middle East pharma market continues to grow, there is an obvious focus on the conservation of temperature and humidity sensitive substances through the supply chain particularly through the summer months. This coupled with the challenges of un-unified cross boarder regulations across the MENA, there is a huge risk to patients and biopharma’s bottom line.
Cold Chain MENA will address how to monitor, control and manage temperatures and other associated risks to biopharma products from manufacturing across the whole supply chain to the end user. Also identifying best practice methodology in the region with global case studies. The interactive forum will also consider regulatory challenges throughout the region and suggest solutions to these challenges.
Event Info:
Date: 07 - 10 November, 2010
Venue: Grand Millennium Dubai, UAE
Website: http://coldchainmena.com
